publication . Article . Other literature type . 2018

PET staging of amyloidosis using striatum

Hanseeuw, Bernard J.; Betensky, Rebecca A.; Mormino, Elizabeth C.; Schultz, Aaron P.; Sepulcre, Jorge; Becker, John A.; Jacobs, Heidi I.L.; Buckley, Rachel F.; LaPoint, Molly R.; Vannini, Patrizia; ...
  • Published: 01 Oct 2018
  • Publisher: Elsevier BV
Abstract
Introduction: Amyloid positron emission tomography (PET) data are commonly expressed as binary measures of cortical deposition. However, not all individuals with high cortical amyloid will experience rapid cognitive decline. Motivated by postmortem data, we evaluated a three-stage PET classification: low cortical; high cortical, low striatal; and high cortical, high striatal amyloid; hypothesizing this model could better reflect Alzheimer’s dementia progression than a model based only on cortical measures. Methods: We classified PET data from 1433 participants (646 normal, 574 mild cognitive impairment, and 213 AD), explored the successive involvement of cortex ...
Subjects
free text keywords: Alzheimer's disease, Article, Amyloid PET imaging, Structural MRI, Striatum, Cortex, Cognitive aging, MCI, Alzheimer’s disease, Classification, Staging, MILD COGNITIVE IMPAIRMENT, PITTSBURGH COMPOUND B, PRECLINICAL ALZHEIMER-DISEASE, NEUROIMAGING INITIATIVE ADNI, A-BETA, PROSPECTIVE COHORT, COMPOSITE SCORE, HUMAN BRAIN, DEPOSITION, DECLINE
Funded by
NIH| Alzheimers Disease Neuroimaging Initiative
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 1U01AG024904-01
  • Funding stream: NATIONAL INSTITUTE ON AGING
,
NIH| Impact of Amyloid and Tau on the Aging Brain: The Harvard Aging Brain Study
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 3P01AG036694-09S2
  • Funding stream: NATIONAL INSTITUTE ON AGING
,
NIH| Disentangling the contribution of tau to aging and AD
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5R01AG046396-05
  • Funding stream: NATIONAL INSTITUTE ON AGING
,
CIHR
Project
  • Funder: Canadian Institutes of Health Research (CIHR)
36 references, page 1 of 3

[1]Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, Cerebral PET with florbetapir compared with n europathology at autopsy for detection of neuritic amyloidbeta plaques: a prospective cohort study. Lancet Neurol 2012; 11:669–78.22749065 [PubMed]

[2]Ikonomovic MD, Buckley CJ, Heurling K, Sherwin P, Jones PA, Zanette M, Post-mortem histopathology underlying beta-amyloid PET imaging following flutemetamol F 18 injection. Acta Neuropathol Commun 2016;4:130.27955679 [OpenAIRE] [PubMed]

[3]Beach TG, Thal DR, Zanette M, Smith A, Buckley C. Detection of striatal amyloid plaques with [18F]flutemetamol: validation with postmortem histopathology. J Alzheimers Dis 2016;52:863–73.27031469 [PubMed]

[4]Caroli A, Prestia A, Galluzzi S, Ferrari C, van der Flier WM, Ossenkoppele R, Mild cognitive impairment with suspected nonamyloid pathology (SNAP): prediction of progression. Neurology 2015;84:508–15.25568301 [OpenAIRE] [PubMed]

[5]Knopman DS, Jack CR Jr, Wiste HJ, Weigand SD, Vemuri P, Lowe V, Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012;78:1576–82.22551733 [OpenAIRE] [PubMed]

[6]Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009;66:1469–75.20008650 [OpenAIRE] [PubMed]

[7]Lim YY, Maruff P, Pietrzak RH, Ellis KA, Darby D, Ames D, Abeta and cognitive change: examining the preclinical and prodromal stages of Alzheimer’s disease. Alzheimers Dement 2014;10:743–751.e1.24589436 [PubMed]

[8]Insel PS, Donohue MC, Mackin RS, Aisen PS, Hansson O, Weiner MW, Cognitive and functional changes associated with Abeta pathology and the progression to mild cognitive impairment. Neurobiol Aging 2016;48:172–81.27710807 [OpenAIRE] [PubMed]

[9]Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol 2013;12:357–67.23477989 [PubMed]

[10]Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791–800.12084879 [PubMed]

[11]Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol 2012;123:1–11.22101365 [OpenAIRE] [PubMed]

[12]Beach TG, Sue LI, Walker DG, Sabbagh MN, Serrano G, Dugger BN, Striatal amyloid plaque density predicts Braak neurofibrillary stage and clinicopathological Alzheimer’s disease: implications for amyloid imaging. J Alzheimers Dis 2012;28:869–76.22112552 [OpenAIRE] [PubMed]

[13]Mormino EC, Papp KV, Rentz DM, Donohue MC, Amariglio R, Quiroz YT, Early and late change on the preclinical Alzheimer’s cognitive composite in clinically normal older individuals with elevated amyloid-beta. Alzheimers Dement 2017;13:1004–12.28253478 [OpenAIRE] [PubMed]

[14]Crane PK, Carle A, Gibbons LE, Insel P, Mackin RS, Gross A, Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav 2012;6:502–16.22782295 [OpenAIRE] [PubMed]

[15]Gibbons LE, Carle AC, Mackin RS, Harvey D, Mukherjee S, Insel P, A composite score for executive functioning, validated in Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav 2012;6:517–27.22644789 [OpenAIRE] [PubMed]

36 references, page 1 of 3
Abstract
Introduction: Amyloid positron emission tomography (PET) data are commonly expressed as binary measures of cortical deposition. However, not all individuals with high cortical amyloid will experience rapid cognitive decline. Motivated by postmortem data, we evaluated a three-stage PET classification: low cortical; high cortical, low striatal; and high cortical, high striatal amyloid; hypothesizing this model could better reflect Alzheimer’s dementia progression than a model based only on cortical measures. Methods: We classified PET data from 1433 participants (646 normal, 574 mild cognitive impairment, and 213 AD), explored the successive involvement of cortex ...
Subjects
free text keywords: Alzheimer's disease, Article, Amyloid PET imaging, Structural MRI, Striatum, Cortex, Cognitive aging, MCI, Alzheimer’s disease, Classification, Staging, MILD COGNITIVE IMPAIRMENT, PITTSBURGH COMPOUND B, PRECLINICAL ALZHEIMER-DISEASE, NEUROIMAGING INITIATIVE ADNI, A-BETA, PROSPECTIVE COHORT, COMPOSITE SCORE, HUMAN BRAIN, DEPOSITION, DECLINE
Funded by
NIH| Alzheimers Disease Neuroimaging Initiative
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 1U01AG024904-01
  • Funding stream: NATIONAL INSTITUTE ON AGING
,
NIH| Impact of Amyloid and Tau on the Aging Brain: The Harvard Aging Brain Study
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 3P01AG036694-09S2
  • Funding stream: NATIONAL INSTITUTE ON AGING
,
NIH| Disentangling the contribution of tau to aging and AD
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5R01AG046396-05
  • Funding stream: NATIONAL INSTITUTE ON AGING
,
CIHR
Project
  • Funder: Canadian Institutes of Health Research (CIHR)
36 references, page 1 of 3

[1]Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, Cerebral PET with florbetapir compared with n europathology at autopsy for detection of neuritic amyloidbeta plaques: a prospective cohort study. Lancet Neurol 2012; 11:669–78.22749065 [PubMed]

[2]Ikonomovic MD, Buckley CJ, Heurling K, Sherwin P, Jones PA, Zanette M, Post-mortem histopathology underlying beta-amyloid PET imaging following flutemetamol F 18 injection. Acta Neuropathol Commun 2016;4:130.27955679 [OpenAIRE] [PubMed]

[3]Beach TG, Thal DR, Zanette M, Smith A, Buckley C. Detection of striatal amyloid plaques with [18F]flutemetamol: validation with postmortem histopathology. J Alzheimers Dis 2016;52:863–73.27031469 [PubMed]

[4]Caroli A, Prestia A, Galluzzi S, Ferrari C, van der Flier WM, Ossenkoppele R, Mild cognitive impairment with suspected nonamyloid pathology (SNAP): prediction of progression. Neurology 2015;84:508–15.25568301 [OpenAIRE] [PubMed]

[5]Knopman DS, Jack CR Jr, Wiste HJ, Weigand SD, Vemuri P, Lowe V, Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012;78:1576–82.22551733 [OpenAIRE] [PubMed]

[6]Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009;66:1469–75.20008650 [OpenAIRE] [PubMed]

[7]Lim YY, Maruff P, Pietrzak RH, Ellis KA, Darby D, Ames D, Abeta and cognitive change: examining the preclinical and prodromal stages of Alzheimer’s disease. Alzheimers Dement 2014;10:743–751.e1.24589436 [PubMed]

[8]Insel PS, Donohue MC, Mackin RS, Aisen PS, Hansson O, Weiner MW, Cognitive and functional changes associated with Abeta pathology and the progression to mild cognitive impairment. Neurobiol Aging 2016;48:172–81.27710807 [OpenAIRE] [PubMed]

[9]Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol 2013;12:357–67.23477989 [PubMed]

[10]Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791–800.12084879 [PubMed]

[11]Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol 2012;123:1–11.22101365 [OpenAIRE] [PubMed]

[12]Beach TG, Sue LI, Walker DG, Sabbagh MN, Serrano G, Dugger BN, Striatal amyloid plaque density predicts Braak neurofibrillary stage and clinicopathological Alzheimer’s disease: implications for amyloid imaging. J Alzheimers Dis 2012;28:869–76.22112552 [OpenAIRE] [PubMed]

[13]Mormino EC, Papp KV, Rentz DM, Donohue MC, Amariglio R, Quiroz YT, Early and late change on the preclinical Alzheimer’s cognitive composite in clinically normal older individuals with elevated amyloid-beta. Alzheimers Dement 2017;13:1004–12.28253478 [OpenAIRE] [PubMed]

[14]Crane PK, Carle A, Gibbons LE, Insel P, Mackin RS, Gross A, Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav 2012;6:502–16.22782295 [OpenAIRE] [PubMed]

[15]Gibbons LE, Carle AC, Mackin RS, Harvey D, Mukherjee S, Insel P, A composite score for executive functioning, validated in Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav 2012;6:517–27.22644789 [OpenAIRE] [PubMed]

36 references, page 1 of 3
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue